These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18488164)

  • 1. Hodgkin's lymphoma relapse in the uterine cervix 15 years after the initial cure.
    Mihaljevic BS; Jovanovic MD; Jakovic LR; Sretenovic AM; Boskovic DV
    Med Oncol; 2008; 25(2):245-7. PubMed ID: 18488164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodular lymphocyte predominant Hodgkin's lymphoma.
    Siddiqui N; Al-Diab AI
    Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
    von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
    Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin's lymphoma involving the uterine cervix after treatment for Hodgkin disease.
    Venizelos ID; Zafrakas M; Dragoumis K; Mandala E; Bondis J
    Leuk Lymphoma; 2003 Dec; 44(12):2155-7. PubMed ID: 14959864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late relapses in Hodgkin's disease: outcome of patients relapsing more than twelve months after primary chemotherapy.
    Salvagno L; Sorarù M; Aversa SM; Bianco A; Chiarion Sileni V; Pappagallo GL; Fiorentino MV
    Ann Oncol; 1993 Sep; 4(8):657-62. PubMed ID: 7694635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
    Vandenberghe P; Wlodarska I; Tousseyn T; Dehaspe L; Dierickx D; Verheecke M; Uyttebroeck A; Bechter O; Delforge M; Vandecaveye V; Brison N; Verhoef GE; Legius E; Amant F; Vermeesch JR
    Lancet Haematol; 2015 Feb; 2(2):e55-65. PubMed ID: 26687610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.
    Ha CS; Kavadi V; Dimopoulos MA; Hagemeister FB; Osborne BM; Fuller LM; Smith TL; Hess MA; McLaughlin PW; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):329-34. PubMed ID: 10030257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebellar involvement in Hodgkin's lymphoma: an atypical site of relapse.
    Sanz A; Montero A; Salas C; Amaya E; Rodríguez G; Magallón R; de la Torre A
    Clin Transl Oncol; 2010 Jun; 12(6):453-5. PubMed ID: 20534402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very late relapse of Hodgkin's disease after 24 years of complete remission.
    Dimopoulos MA; Kostis E; Anagnostopoulos A; Dalezios M; Papadimitris C; Papadimitriou C
    Leuk Lymphoma; 1997 Dec; 28(1-2):215-7. PubMed ID: 9498723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases.
    Zarate-Osorno A; Medeiros LJ; Kingma DW; Longo DL; Jaffe ES
    Am J Surg Pathol; 1993 Feb; 17(2):123-32. PubMed ID: 8422110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
    Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology of Hodgkin's lymphoma.
    Eberle FC; Mani H; Jaffe ES
    Cancer J; 2009; 15(2):129-37. PubMed ID: 19390308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical Hodgkin's lymphoma presenting as a testicular mass: report of a case.
    Seliem RM; Chikwava K; Swerdlow SH; Young RH; Ferry JA
    Int J Surg Pathol; 2007 Apr; 15(2):207-12. PubMed ID: 17478785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
    Krugmann J; Tzankov A; Gschwendtner A; Fischhofer M; Greil R; Fend F; Dirnhofer S
    Mod Pathol; 2003 Jun; 16(6):566-73. PubMed ID: 12808062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.